Patrice Herait

6.8k total citations · 4 hit papers
70 papers, 4.9k citations indexed

About

Patrice Herait is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Patrice Herait has authored 70 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 36 papers in Oncology and 21 papers in Hematology. Recurrent topics in Patrice Herait's work include Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (19 papers) and Cancer Treatment and Pharmacology (17 papers). Patrice Herait is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (19 papers) and Cancer Treatment and Pharmacology (17 papers). Patrice Herait collaborates with scholars based in France, Switzerland and United Kingdom. Patrice Herait's co-authors include Lucile Awad, Christian Jacques, David Cunningham, D Abigerges, G G Chabot, Cornelis J.A. Punt, Tamas Hickish, Reino Heikkilä, R.D. James and Tom Børge Johannesen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Patrice Herait

69 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1998 973 citations David Cunningham, Lucile Awad et al. The Lancet profile →
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

1998 786 citations Philippe Rougier, Eric Van Cutsem et al. The Lancet profile →
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Keyvan Rezaï, Patrice Herait et al. The Lancet Haematology profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Sandy Amorim, Anastasios Stathis et al. The Lancet Haematology profile →

Peers

Countries citing papers authored by Patrice Herait

Since Specialization

Citations

This map shows the geographic impact of Patrice Herait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrice Herait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrice Herait more than expected).

Fields of papers citing papers by Patrice Herait

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrice Herait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrice Herait. The network helps show where Patrice Herait may publish in the future.

Co-authorship network of co-authors of Patrice Herait

This figure shows the co-authorship network connecting the top 25 collaborators of Patrice Herait. A scholar is included among the top collaborators of Patrice Herait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrice Herait. Patrice Herait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study breakdown → 2016 ·The Lancet Haematology ·Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezaï, Patrice Herait, Carmen Kahatt, François Lokiec, Gilles Salles, Thierry Façon, Antonio Palumbo, David Cunningham, Emanuele Zucca, Catherine Thiéblemont	328
2	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs 2015 ·Clinical Cancer Research ·Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni, Afua A. Mensah, Anastasios Stathis, Georg Stüssi, María E. Riveiro, Patrice Herait, Giorgio Inghirami, Esteban Cvitkovic, Emanuele Zucca, Francesco Bertoni	214
3	Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial 2011 ·Annals of Oncology ·Jean-Philippe Durand, G. Deplanque, (unknown), J.M. Gornet, F. Scotté, Olivier Mir, Anatole Cessot, Romain Coriat, Éric Raymond, Emmanuel Mitry, Patrice Herait, Y. Yataghene, François Goldwasser	144
4	Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study 2006 ·Annals of Oncology ·J. Alexandre, Elisabeth Rey, V. Girre, Sophie Grabar, A. Tran, (unknown), (unknown), Véronique Dièras, Vincent Jullien, Patrice Herait, Gérard Pons, Jean‐Marc Tréluyer, François Goldwasser	51
5	Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study 2006 ·Annals of Oncology ·Pascal Piedbois, D. Serin, Franck Priou, (unknown), (unknown), (unknown), É. Teissier, Jean François Berdah, Michel Fabbro, B. Valenza, Patrice Herait, Valentine Jehl, Marc Buyse	30
6	Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients 2004 ·Annals of Oncology ·L. Cals, Olivier Rixe, Éric François, R. Favre, (unknown), G. Deplanque, Abderrahmane Laadem, (unknown), Jean-Marc Béréder, David Bernardini, Patrice Herait	23
7	Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed 2002 ·Journal of Clinical Oncology ·Michael J. Keating, Bruno Cazin, Steven Coutré, Ruemu Birhiray, Tibor Kovacsovics, Wolfgang Langer, Brian Leber, T.S. Maughan, R. Kanti, Geir E. Tjønnfjord, (unknown), M. Itzhaki, Patrice Herait	73
8	Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer breakdown → 1998 ·The Lancet ·Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, N. Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, J. Wils, Lucile Awad, Patrice Herait, Christian Jacques	786
9	Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. 1998 ·Journal of Clinical Oncology ·Faouzi Saliba, (unknown), J. L. Misset, G. Bastian, Gilles Vassal, M. Bonnay, Patrice Herait, Claudia Côté, Mondher Mahjoubi, D. Mignard, Esteban Cvitkovic	112
10	Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. 1996 ·Journal of Clinical Oncology ·Pierre Canal, Caryl Gay, (unknown), Jean‐Yves Douillard, R. Bugat, R. Brunet, Antoine Adenis, Patrice Herait, François Lokiec, A. Mathieu-Boué	98
11	Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. 1995 ·Journal of Clinical Oncology ·D Abigerges, G G Chabot, Jean‐Pierre Armand, Patrice Herait, Alain Gouyette, Daniel Gandía	249
12	Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials 1995 ·Annals of Oncology ·G G Chabot, D Abigerges, G. Catimel, Stéphane Culine, M Forni, Jean Marc Extra, M. Mahjoubi, Patrice Herait, Jean‐Pierre Armand, R. Bugat, (unknown), (unknown)	149
13	CPT-11 (Irinotecan) in the treatment of colorectal cancer 1995 ·European Journal of Cancer ·Jean‐Pierre Armand, Michel Ducreux, M. Mahjoubi, D Abigerges, R. Bugat, G G Chabot, Patrice Herait, M Forni, P Rougier	97
14	Phase II Trial of Pirarubicin in the Treatment of Advanced Pancreatic Cancer 1994 ·Cancer Investigation ·Mondher Mahjoubi, Philippe Rougier, (unknown), Patrice Herait, Jean‐Marie Tigaud, Jean‐Pierre Droz	4
15	Phase II Trials of Tetrahydropyranyl-Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma 1993 ·American Journal of Clinical Oncology ·H. Roché, (unknown), Pierre Kerbrat, Paul Rebattu, P. Fargeot, A Cattan, Jean‐Pierre Armand, R Keiling, M.A. Lentz, (unknown), Patrice Herait, P. Fumoleau	4
16	Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC) 1993 ·European Journal of Cancer ·J Chauvergne, P. Fumoleau, P Cappelaere, R Metz, P. Armand, B Chevallier, Pierre Kerbrat, M Forni, C. Lhommé, Henri Roché, P. Chollet, A Goupil, (unknown), Patrice Herait, M.A. Lentz	13
17	Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. 1992 ·PubMed ·B Chevallier, L. Mignot, T. Delozier, F. Morvan, Christophe Fermé, Patrice Herait	6
18	Phase II trial of pirarubicin in the treatment of advanced bladder cancer 1992 ·Investigational New Drugs ·M. Mahjoubi, Joseph Kattan, Marwan Ghosn, J.P. Droz, (unknown), Patrice Herait	5
19	Association of Bolus Tetrahydropyranyl Adriamycin and 120 Hours Continuous 5-Fluorouracil Infusion in Patients with Metastatic Breast Cancer 1990 ·American Journal of Clinical Oncology ·(unknown), P. Fumoleau, Pierre Kerbrat, Alain Monnier, Henri Roché, Marcus J. Goudie, Patrice Herait	3
20	Phase II study of pirarubicin in advanced non-small cell lung cancer 1989 ·European Journal of Cancer and Clinical Oncology ·P. Berthaud, Thierry Le Chevalier, J. Bérille, Patrice Herait, P Baldeyrou, Thomas Tursz, R. Arriagada, (unknown), Marcel Hayat	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact